Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,501–1,600 of 2,576
Pathogenesis of Alzheimer’s Disease
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_162 · Cited by 24
Potential novel targets for Alzheimer pharmacotherapy: I. Secretases
Maiorini, A. F., Gaunt, M., Jacobsen, T., McKay, A. E., Waldman, L., & Raffa, R. B. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00415.x · Cited by 26
MULTIPLE PATHWAYS OF DNA DISINTEGRATION DURING NEURONAL APOPTOSIS
Bezvenyuk, Z. (2001) · Cited by 39
γ-Secretase: Substrates and Inhibitors
Rochette, M. J., & Murphy, M. P. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:1:081 · Cited by 29
“responsible for most cases of early-onset FAD, with the mechanism being via a selective increase in the production of Aβ42 (37).”
BackgroundRacchi, M., Ianna, P., Binetti, G. G., Trabucchi, M., & Govoni, S. M. (1998) · Biochemical Journal · doi:10.1042/bj3301271 · Cited by 26
Presenilins, β-amyloid precursor protein and the molecular basis of Alzheimer's disease
Selkoe, D. J. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(00)00016-5 · Cited by 31
Self-citationMyers, A., Marshall, H. N., Holmans, P., Compton, D., Crook, R., Mander, A., Nowotny, P., Smemo, S., Dunstan, M. L., Jehu, L., et al. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20036 · Cited by 24
“…for the rare familial forms of AD produce more Ab by increasing either b- or g-cleavage of APP [Citron et al., 1992, 1997; Hsiao et al., 1996; Scheuner et al., 1996], APOE, the only known risk factor for LOAD, appears to act by affecting the deposition of fibrillar forms of Ab [Holtzman et…”
BackgroundSelf-citationMolecular signatures of neurodegeneration in the cortex of PS1/PS2 double knockout mice
Mirnics, K., Norstrom, E. M., Garbett, K., Choi, S., Zhang, X., Ebert, P., & Sisodia, S. S. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-14 · Cited by 23
Chiu, Y. W., Hori, Y., Ebinuma, I., Sato, H., Hara, N., Ikeuchi, T., & Tomita, T. (2020) · The FASEB Journal · doi:10.1096/fj.201902966rr · Cited by 25
Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice
Ruiz‐Riquelme, A., Mao, A., Barghash, M. M., Lau, H. H. C., Stuart, E., Kovács, G. G., Nilsson, K. P. R., Fraser, P. E., Schmitt‐Ulms, G., & Watts, J. C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01187-6 · Cited by 25
Islam, S., Sun, Y., Gao, Y., Nakamura, T., Noorani, A. A., Li, T., Wong, P. C., Kimura, N., Matsubara, E., Kasuga, K., et al. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.2039-21.2021 · Cited by 28
An Alternative View of Familial Alzheimer’s Disease Genetics
Lardelli, M. T. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230313 · Cited by 24
“Changes in A (cid:2) 42 /A (cid:2) 40 ratios have also been observed in in vitro analyses of fAD mutations of PSEN1 [35–37] and PSEN2 [39–41] (discussed later herein).”
Amyloid-β42 Plasma Levels are Elevated in Amnestic Mild Cognitive Impairment
Cammarata, S., Borghi, R., Giliberto, L., Pardini, M., Pollero, V., Novello, C., Fornaro, M., Vitali, A., Bracco, L., Caltagirone, C., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1144 · Cited by 24
“phase, the increase in Aβ42 in the brain is paralleled by elevated levels of Aβ42 in plasma [3–5].”
Essential role of POLDIP2 in Tau aggregation and neurotoxicity via autophagy/proteasome inhibition
Kim, Y. D., Park, H., Nah, J., Moon, S., Lee, W., Hong, S.-H., Kam, T., & Jung, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.084 · Cited by 25
Dynamin 1 depletion and memory deficits in rats treated with Aβ and cerebral ischemia
Watanabe, T., Iwasaki, K., Takasaki, K., Yamagata, N., Fujino, M., Nogami, A., Ii, M., Katsurabayashi, S., Mishima, K., & Fujiwara, M. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22346 · Cited by 26
“In addition, the 10:1 ratio of Ab40 and Ab42 that we used seems to mimic the ratio reported in some familial AD mutants (Scheuner et al., 1996).”
ResultKimpe, L. D., & Scheper, W. (2009) · Current Medicinal Chemistry · doi:10.2174/092986710790149765 · Cited by 26
“All these mutations can directly be linked to altered or increased A formation [3-7].”
BackgroundModulation of transient receptor potential melastatin related 7 channel by presenilins
Oh, H. G., Chun, Y. S., Kim, Y., Youn, S. H., Shin, S., Park, M. K., Kim, T., & Chung, S. (2011) · Developmental Neurobiology · doi:10.1002/dneu.22001 · Cited by 28
“DOI 10.1002/dneu.22001 865 role of PS as catalytic subunit of c-secretase, FAD mutations in PSs affect APP processing increasing the ratio of Ab42 to Ab40 (Scheuner et al., 1996).”
BackgroundInfluentialSPF-5506-A4, a New Peptaibol Inhibitor of Amyloid β-Peptide Formation Produced by Trichoderma sp.
Hosotani, N., Kumagai, K., Honda, S., Itô, A., Shimatani, T., & Saji, I. (2007) · The Journal of Antibiotics · doi:10.1038/ja.2007.20 · Cited by 23
Delacourte, A., Campion, D., & Davous, P. (2007) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(07)44093-3 · Cited by 25
Barrera-Ocampo, A. A., Arlt, S., Matschke, J., Hartmann, U., Puig, B., Ferrer, I., Zürbig, P., Glatzel, M., Falla, D. S., & Jahn, H. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw065 · Cited by 27
“However, the mechanisms of Ab increased production in late-onset sporadic AD are not well understood (5).”
BackgroundPark, J., Han, S., Byun, M. S., Yi, D., Lee, J. H., Park, K., Lee, D. Y., & Mook‐Jung, I. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00362 · Cited by 25
“Cerebral β-amyloid (Aβ) plaques and neurofibrillary tangles (NFT) are characteristics of AD (Hardy and Higgins, 1992; Scheuner et al., 1996; Wisniewski et al., 1997; Murphy and LeVine, 2010; Bloom, 2014).”
BackgroundBate, C., & Williams, A. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100528 · Cited by 25
Satoh, & Kuroda (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00209.x · Cited by 23
Bradykinin receptor modulation in cellular models of aging and Alzheimer's disease
Jong, Y.-J. I., Dalemar, L., Seehra, K., & Baenziger, N. L. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00168-6 · Cited by 23
Generation of a recombinant Fab antibody reactive with the Alzheimer's disease-related Aβ peptide
Tammer, A., Coia, G., Cappai, R., Fuller, S. J., Masters, C. L., Hudson, P. J., & Underwood, J. R. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01905.x · Cited by 24
Shi, J., Tian, J., Pritchard, A. L., Lendon, C. L., Lambert, J., Iwatsubo, T., & Mann, D. M. A. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1108-3 · Cited by 23
“with mutations in APP, PS-1 or PS-2 genes, is likely the result of overproduction of Ab, particularly Ab42 [27] relative to clearance, whereas in late-onset AD the”
BackgroundPresenilin‐1‐mediated Retention of APP Derivatives in Early Biosynthetic Compartments
Réchards, M., Xia, W., Oorschot, V. M. J., van Dijk, S., Annaert, W. G., Selkoe, D. J., & Klumperman, J. (2006) · Traffic · doi:10.1111/j.1600-0854.2006.00388.x · Cited by 23
Self-citationVestling, M., Cedazo-Mínguez, Á., Adem, A., Wiehager, B., Racchi, M., Lannfelt, L., & Cowburn, R. F. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(99)00003-4 · Cited by 23
Self-citationInoue, K., Oliveira, L. M. A., & Abeliovich, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.075 · Cited by 25
“Altered APP processing has been described even in skin fibroblasts from FAD patients, despite the apparent absence of AD pathology in the skin (Scheuner et al., 1996; Connolly, 1998; Etcheberrigaray and Bhagavan, 1999; Kondo et al., 2013).”
BackgroundResultBosentan preserves endothelial function in mice overexpressing APP
Elesber, A. A., Bonetti, P. O., Woodrum, J. E., Zhu, X.-Y., Lerman, L. O., Younkin, S. G., & Lerman, A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.012 · Cited by 26
Self-citationHonda, T., Nihonmatsu, N., Yasutake, K., Ohtake, A., Sato, K., Tanaka, S., Murayama, O., Murayama, M., & Takashima, A. (2000) · Neuroscience Research · doi:10.1016/s0168-0102(00)00106-1 · Cited by 25
“…increase the level of the secreted b-amyloid peptide terminating at amino acid 42 (Ab42) in cultured cells and transgenic mice (Martins et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Lemere et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Tomita et al., 1997; Xia et al., 1997).”
BackgroundMarutle, A., Unger, C., Hellström‐Lindahl, E., Wang, J., Puoliväli, J. T., Tanila, H., Nordberg, A. K., & Zhang, X. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00546-3 · Cited by 24
Krezowski, J., Knudson, D., Ebeling, C., Pitstick, R., Giri, R. K., Schenk, D., Westaway, D., Younkin, L., Younkin, S. G., Ashe, K. H., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh210 · Cited by 30
“Plasma Ab40 and Ab42 concentrations were determined using the BAN-50/ BA-27 and BAN-50/BC005 sandwich ELISA assay as previously described ( 50 ).”
MethodAβ immunization: Moving Aβ peptide from brain to blood
Lee, V. M. ‐. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171311798 · Cited by 25
Pedersen, W. A., Guo, Q., Hartman, B. K., & Mattson, M. P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22397 · Cited by 24
Popescu, B. O., Cedazo-Mínguez, Á., Benedikz, E., Nishimura, T., Winblad, B. G., Ankarcrona, M., & Cowburn, R. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306041200 · Cited by 24
Presenilins as endoplasmic reticulum calcium leak channels and Alzheimer’s disease pathogenesis
Supnet, C. B., & Борисович, Б. И. (2011) · Science China Life Sciences · doi:10.1007/s11427-011-4201-y · Cited by 25
Cell size effects in the molecular dynamics of the intrinsically disordered Aβ peptide
Mehra, R., & Kepp, K. P. (2019) · The Journal of Chemical Physics · doi:10.1063/1.5115085 · Cited by 24
RS‐4252 Inhibits Amyloid β‐Induced Cytotoxicity in HeLa Cells
Nishimura, S., Murasugi, T., Kubo, T., Kaneko, I., Meguro, M., Marumoto, S., Kogen, H., Koyama, K., Oda, T., & Nakagami, Y. (2003) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2003.930104.x · Cited by 28
Aminothiazoles as γ-secretase modulators
Lübbers, T., Flohr, A., Jolidon, S., David‐Pierson, P., Jacobsen, H., Ozmen, L., & Baumann, K. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.060 · Cited by 22
Cerebrospinal fluid Aβ 42 levels and APP processing pathway genes in Parkinson's disease
Bekris, L. M., Tsuang, D. W., Peskind, E. R., Yu, C., Montine, T. J., Zhang, J., Zabetian, C. P., & Leverenz, J. B. (2015) · Movement Disorders · doi:10.1002/mds.26172 · Cited by 22
Self-citationA Systems View of the Differences between APOE ε4 Carriers and Non-carriers in Alzheimer’s Disease
Jiang, S., Tang, L. Y., Zhao, N., Yang, W., Qiu, Y. L., & Chen, H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00171 · Cited by 24
“Another TF of 14-base motif, named EGR1, up-regulates the PSEN2 gene in neuronal cells (Renbaum et al., 2003).”
BackgroundPark, M. H., Yun, H., Hwang, C. J., Park, S. I., Han, S., Hwang, D. Y., Yoon, D., Kim, S., & Hong, J. T. (2017) · Theranostics · doi:10.7150/thno.21408 · Cited by 22
One for all and all for One: Improving replication of genetic studies through network diffusion
Lancour, D., Naj, A., Mayeux, R., Haines, J. L., Pericak-Vance, M. A., Schellenberg, G. D., Crovella, M., Farrer, L. A., & Kasif, S. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007306 · Cited by 23
Self-citationDehury, B., Somavarapu, A. K., & Kepp, K. P. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2020.107648 · Cited by 22
γ-Secretase Modulatory Proteins: The Guiding Hand Behind the Running Scissors
Wong, E., Frost, G. R., & Li, Y.-M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.614690 · Cited by 22
“(1) FAD mutations in PSEN1 and PSEN2 increase in the ratio of Aβ42 to Aβ40 in transfected cells and in transgenic mice (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; De Strooper, 2007; Wolfe, 2007).”
BackgroundCompact fibril-like structure of amyloid β-peptide (1–42) monomers
Barz, B., Buell, A. K., & Nath, S. (2021) · Chemical Communications · doi:10.1039/d0cc06607a · Cited by 23
Murakami, K., Masuda, Y., Shirasawa, T., Shimizu, T., & Irie, K. (2010) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2010.00598.x · Cited by 25
DEFELICE, F. G., & Ferreira, S. T. (2002) · Anais da Academia Brasileira de Ciências · doi:10.1590/s0001-37652002000200006 · Cited by 29
“…between production and catabolism ofAβ appears directly related toAlzheimer’s disease, as the over-production ofβ-amyloid peptide is not followed by a parallel increase in its clearance in both familiar and sporadic forms of AD (Scheuner et al. 1996, Hardy 1997, Selkoe 1998, Price et al. 1998).”
BackgroundMolecular basis of Alzheimer’s disease
Grigorenko, A. P., & Rogaev, E. I. (2007) · Molecular Biology · doi:10.1134/s0026893307020100 · Cited by 22
“An increased Aβ42/43 level was observed in the culture medium of fibroblasts isolated from AD patients [40].”
BackgroundPoly-l-lysine Dissolves Fibrillar Aggregation of the Alzheimer β-Amyloid Peptide in Vitro
Nguyen, K. V., Gendrault, J., & Wolff, C.-M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6514 · Cited by 22
Reduction of Plasma Glutamyl Aminopeptidase Activity in Sporadic Alzheimer's Disease
Kuda, T., Shoji, M., Arai, H., Kawashima, S., & Saido, T. C. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.5920 · Cited by 25
Presenilin, γ-Secretase, and the Search for Pathogenic Triggers of Alzheimer’s Disease
Wolfe, M. S. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00830 · Cited by 21
γ‐Secretase in microglia – implications for neurodegeneration and neuroinflammation
Walter, J., Kemmerling, N., Wunderlich, P., & Glebov, K. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14224 · Cited by 25
Ran, Y., Cruz, P. E., Ladd, T. B., Fauq, A. H., Jung, J. I., Matthews, J., Felsenstein, K. M., & Golde, T. E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512921 · Cited by 21
Impact of sequence on the molecular assembly of short amyloid peptides
Wagoner, V. A., Cheon, M., Chang, I., & Hall, C. K. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24515 · Cited by 21
Am, A., Uddin, M. S., Wahid, F., Mohammed, A. I., & Rahman, M. M. (2016) · Journal of Neurology and Neuroscience · doi:10.21767/2171-6625.1000126 · Cited by 22
Þórðardóttir, S., Rodriguez‐Vieitez, E., Almkvist, O., Ferreira, D., Saint‐Aubert, L., Ståhlbom, A. K., Thonberg, H., Schöll, M., Westman, E., Wall, A. E., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0374-y · Cited by 23
“PSEN1 mutations cause a relative increase in the ratio of amyloid-β42 to amyloid-β40 through an increase in amyloid-β42 production, a decrease in amyloidβ40 production, or both [15].”
Metallomics Applied to the Study of Neurodegenerative and Mental Diseases
Sussulini, A., & Hauser‐Davis, R. A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-90143-5_2 · Cited by 23
Tao, P.-F., & Huang, H. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00574 · Cited by 21
Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator
Jung, J. I., Price, A. R., Ladd, T. B., Ran, Y., Park, H.-J., Ceballos‐Diaz, C., Smithson, L. A., Hochhaus, G., Tang, Y., Akula, R., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0021-z · Cited by 25
“Many early onset familial AD (FAD) mutations linked with APP and Presenilin (PSEN, the catalytic subunit of γ-secretase) increase the relative levels of Aβ42 [7–10].”
BackgroundLahiri, D. K., & Maloney, B. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120373 · Cited by 22
“Furthermore, specific mutations in the presenilin genes (PSEN1, PSEN2) also produce AD in an autosomally dominant manner [14, 15].”
BackgroundAmyloid peptide toxicity and microtubule-stabilizing drugs
Michaelis, M. L., Chen, Y., Hill, S., Reiff, E., Georg, G. I., Rice, A., & Audus, K. L. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0018-2 · Cited by 23
“…pathogenesis of AD is strongly supported by the genetics of abnormalities in the amyloid precursor protein (APP) (e.g., Mullan and Crawford, 1993) and the enhanced A 1-42 formation and deposition in senile plaques in individuals with mutations in the presenilin genes (e.g., Scheuner et al., 1996).”
BackgroundStoppini, M., Andreola, A., Foresti, G., & Bellotti, V. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.025 · Cited by 21
Day, G. S., Musiek, E. S., Roe, C. M., Norton, J. B., Goate, A., Cruchaga, C., Cairns, N. J., & Morris, J. C. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1236 · Cited by 23
Kilian, J., Hsu, H.-W., Mata, K., Wolf, F. W., & Kitazawa, M. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.02.011 · Cited by 25
‘Nature-inspired’ drug–protein complexes as inhibitors of Aβ aggregation
Bose, M., Gestwicki, J. E., Devasthali, V., Crabtree, G. R., & Graef, I. A. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330543 · Cited by 21
Pathways to Primary Neurodegenerative Disease
Hardy, J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05556.x · Cited by 21
Self-citationEtcheberrigaray, R., & Bhagavan, S. (1999) · Molecular Neurobiology · doi:10.1007/bf02742436 · Cited by 24
“This finding in the Swedish family was later shown for various PS1 and PS2 mutations in particular, for the amount of the longer A~ 1-42 form (106).”
BackgroundSudoh, S., Hua, G., Kawamura, Y., Maruyama, K., Komano, H., & Yanagisawa, K. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01206.x · Cited by 22
Casamenti, F., Prosperi, C., Scali, C., Giovannelli, L., & Pepeu, G. (1998) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(98)00080-x · Cited by 24
Melcangi, R. C., Magnaghi, V., Cavarretta, I., Zucchi, I., Bovolin, P., D'Urso, D., & Martini, L. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990515)56:4<349::aid-jnr3>3.0.co;2-h · Cited by 123
Alzheimer Disease Research Comes of Age The Pace Accelerates
Morrison‐Bogorad, M. (1997) · JAMA · doi:10.1001/jama.1997.03540340071036 · Cited by 20
Fowler, C. J. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00024-6 · Cited by 21
Detection of Preclinical Alzheimer's Disease
Skoog, I. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430709 · Cited by 24
The Spectrum of Genetic Risk in Alzheimer Disease
Karagas, N. E., Young, J. E., Blue, E., & Jayadev, S. (2025) · Neurology Genetics · doi:10.1212/nxg.0000000000200224 · Cited by 25
Roed, L., Grave, G., Lindahl, T., Rian, E., Horndalsveen, P. O., Lannfelt, L., Nilsson, C. F., Swenson, F. J., Lönneborg, A., Sharma, P., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122404 · Cited by 25
“: +47 23 24 89 50; Fax: +47 23 24 89 59; E-mail: line.roed@diagenic.com.”
Self-citationMcInerney, M. P., Short, J. L., & Nicolazzo, J. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0077-5 · Cited by 22
Comparison of longitudinal Aβ in non-demented elderly and Down syndrome
Tudorascu, D., Anderson, S., Minhas, D., Yu, Z., Comer, D. M., Lao, P., Hartley, S., Laymon, C., Snitz, B., Lopresti, B., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.030 · Cited by 17
Molecular Recipe for γ-Secretase Modulation from Computational Analysis of 60 Active Compounds
Tang, N., Somavarapu, A. K., & Kepp, K. P. (2018) · ACS Omega · doi:10.1021/acsomega.8b02196 · Cited by 22
Simple model systems reveal conserved mechanisms of Alzheimer’s disease and related tauopathies
Jiang, Y., & MacNeil, L. T. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00664-x · Cited by 24
Meng, F., Kim, J.-Y., Louis, J. M., & Chung, H. S. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06372 · Cited by 20
Transgenic Models of Alzheimer's Disease
Sugarman, M. C., Hinton, S. F., & LaFerla, F. M. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-006-3_2 · Cited by 20
Payette, D. J., Xie, J., & Guo, Q. (2006) · Brain Research · doi:10.1016/j.brainres.2006.12.005 · Cited by 22
“…aberrant production and aggregation of amyloid β-peptide (Annaert et al., 1999; Borchelt et al., 1997; Cai et al., 2006; Capell et al., 2000; Chui et al., 1999; Duff et al., 1996; Guo et al., 1996; Guo et al., 1997; Guo et al., 1998; Guo et al., 1999c; Mattson et al., 1998; Scheuner et al., 1996).”
BackgroundEhling, R., Nosková, L., Stránecký, V., Hartmannová, H., Přistoupilová, A., Hodaňová, K., Benke, T., Kovács, G. G., Ströbel, T., Niedermüller, U., et al. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.01.017 · Cited by 23
“A number of PSEN1missensemutations alter the specificity of γ-secretase cleavage leading to increased proportions of longer forms of amyloid-β peptide (Aβ), which are prone to oligomerization and aggregation in amyloid plaques [9,10].”
BackgroundTranscriptional Regulation of TMP21 by NFAT
Liu, S., Zhang, S., Bromley‐Brits, K., Cai, F., Zhou, W., Xia, K., Mittelholtz, J., & Song, W. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-21 · Cited by 23
“PS mutant forms have been shown to increase g-secretase activity, resulting in elevated Ab42 production [17-19].”
BackgroundAmyloid Beta Peptide Is Released during Thrombosis in the Skin
Kucheryavykh, L. Y., Kucheryavykh, Y. V., Washington, A. V., & Inyushin, M. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061705 · Cited by 21
Wang, M., Lv, J., Huang, X., Wısnıewskı, T., & Zhang, W. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00890-9 · Cited by 22
High Serum Aβ and Vascular Risk Factors in First-Degree Relatives of Alzheimer’s Disease Patients
Abdullah, L. I., Luis, C. A., Paris, D., Ait‐Ghezala, G., Mouzon, B., Allen, E., Parrish, J., Mullan, M. A., Ferguson, S., Wood, M., et al. (2009) · Molecular Medicine · doi:10.2119/molmed.2008.00118 · Cited by 22
“Dihydropyridine 18 (9) Nondihydropyridine 2 (1) Angiotensin-converting enzyme 46 (23) inhibitor Angiotensin II receptor blockers 21 (11) Statin 84 (43) Placebo 83 (42) Celecoxib 52 (26) Naproxen 62 (32)”
BackgroundCleavage Agents for Soluble Oligomers of Amyloid β Peptides
Suh, J., Yoo, S. H., Kim, M. G., Jeong, K., Ahn, J. Y., Kim, M., Chae, P. S., Lee, T. Y., Lee, J.-H., Lee, J., et al. (2007) · Angewandte Chemie · doi:10.1002/ange.200702399 · Cited by 21
Fernandez, L. L., Carmona, M., Portero‐Otín, M., Naudí, A., Pamplona, R., Schröder, N., & Ferrer, I. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1304 · Cited by 23
“The mouse line used in this study expressed a Mo/Hu AβPP695swe construct in conjunction with the exon-9-deleted variant of human presenilin 1 (PS1-dE9) [8].”
BackgroundMethodEyre, L. J., Rabbitt, E. H., Bland, R., Hughes, S. V., Cooper, M. S., Sheppard, M. C., Stewart, P. M., & Hewison, M. (2001) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010601)81:3<453::aid-jcb1059>3.0.co;2-z · Cited by 35
Novel aspects of accumulation dynamics and Aβ composition in transgenic models of AD
Lewis, H. D., Beher, D., Smith, D., Hewson, L., Cookson, N., Reynolds, D. S., Dawson, G. R., Jiang, M., der Ploeg, L. H. T. V., Qian, S., et al. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.009 · Cited by 22
“The majority of FAD mutations are found in PS1, a polytopic membrane protein intimately associated with -secretase activity, and such mutations in PS1 have been widely shown to increase the production of amyloid peptides ending at residue 42 in vitro and in vivo [31].”
BackgroundYasuda, M., Hirono, N., Maeda, K., Imamura, T., Mori, E., & Tanaka, C. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.6.722 · Cited by 25
Mitochondrial Genome Lesions in the Pathogenesis of Sporadic Alzheimer’s Disease
Meier‐Ruge, W., & Bertoni–Freddari, C. (1999) · Gerontology · doi:10.1159/000022104 · Cited by 21
Alkon, D. L. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991001)58:1<24::aid-jnr4>3.0.co;2-n · Cited by 20
Platelet secretion of β-amyloid is increased in hypercholesterolaemia
Smith, C., Hyatt, P. J., Stanyer, L., & Betteridge, D. J. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02080-7 · Cited by 21
Evidence against association of the FE65 gene (APBB1) intron 13 polymorphism in Alzheimer's patients
Guénette, S. Y., Bertram, L., Crystal, A., Bakondi, B., Hyman, B. T., Rebeck, G. W., Tanzi, R. E., & Blacker, D. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01607-4 · Cited by 20
Self-citationNeurodegenerative disease: a different view of diagnosis
Hardy, J., & Gwinn, K. A. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01604-4 · Cited by 20
Self-citationIrving, N. G., & Miller, C. C. J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13343-2 · Cited by 20
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.